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InﬂammationThe cytokine stormwhich is a great burden on humanity in highly pathogenic inﬂuenza virus infections requires
activation of multiple signaling pathways. These pathways, such as MAPK and JNK, are important for viral repli-
cation and host inﬂammatory response. Here we examined the roles of JNK downstreammolecule c-jun in host
inﬂammatory responses and H5N1 virus replication using a c-jun targeted DNAzyme (Dz13). Transfection of
Dz13 signiﬁcantly reduced H5N1 inﬂuenza virus replication in human lung epithelial cells. Concomitantly,
there was a decreased expression of pro-inﬂammatory cytokines (tumor necrosis factor (TNF)-α, interferon
(IFN)-β and interleukin (IL)-6) in c-jun suppressed cells, while the expression of anti-inﬂammatory cytokines,
such as IL-10, was increased. In vivo, compared with control groups, suppression of c-jun improved the survival
rate of mice infected with H5N1 virus (55.5% in Dz13 treated mice versus ≤11% of control mice) and decreased
the CD8+ T cell proliferation. Simultaneously, the pulmonary inﬂammatory response and viral burden also de-
creased in the Dz13 treated group. Thus, our data demonstrated a critical role for c-jun in the establishment of
H5N1 infection and subsequent inﬂammatory reactions, which suggest that c-junmay be a potential therapeutic
target for viral pneumonia.
© 2014 The Authors. Published by Elsevier B.V. All rights reserved.1. Introduction
Inﬂuenza A virus (IAV) remained to be a common pathogen causing
high morbidity and signiﬁcant mortality worldwide [1]. Highly patho-
genic IAV H5N1 can cause acute respiratory infections in both poultry
and humans; the mortality rate of human infected H5N1 is about 60%
[2,3]. Furthermore, the inﬂuenza A virus including H5N1 may causegetedDNAzyme;ATF, activating
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. All rights reserved.pandemics because of its antigenic drift or antigenic shift [1], and thus
is a major burden for public health worldwide.
Numerous studies have attempted to determine the reasons for high
mortality of H5N1 infection. High viral load and the resulting intense in-
ﬂammatory response were reported to be responsible for disease sever-
ity [4]. H5N1 virus infection induces high viral load in pharyngeal and
frequent viral RNA detection in blood, leading to over-expression of
inﬂammatory cytokines, such as tumor necrosis factor (TNF)-α, inter-
feron (IFN)-γ, IFN-α/β, interleukin (IL)-6, IL-1, and so on. The excessive
levels of pro-inﬂammatory cytokine production also named “cytokine
storm”, has been suggested as the direct reason for the lethal clinical
symptoms, for example, extensive pulmonary edema, acute broncho-
pneumonia and alveolar hemorrhage [5,6]. Therefore, the development
of a therapeutic agent to inhibit IAV replication and limit host inﬂamma-
tion without having deleterious side effects on innate immunity is
urgently required.
Vaccination against inﬂuenza remains the most effective preventive
measure, but may become less effective because of the antigenic varia-
tion of IAV [7]. Alternatively, antiviral drugs such as zanamiver
(Relenza) and oseltamivir (Tamiﬂu) have proven to be efﬁcient, but
Fig. 1. c-jun activation in the early stage of H5N1 infection inA549 cells. (A) c-jun is phosphorylated uponH5N1 infection inA549 cells. A549 cellswere infectedwithH5N1 and cell lysates
were analyzed by Western blotting. Relative band intensity was determined digitally using QuantityOne 4.1.1 software and is expressed as a ratio of c-Jun to β-actin. (B) Replication of
H5N1 virus in A549 cells. A549 cells were infected with H5N1 and the viral titer was analyzed by real-time PCR using primers speciﬁc for the HA gene. p-c-jun: phosphorylated c-jun;
t-c-jun: total c-jun(N = 3).
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their therapeutic application [8,9].
It has been suggested that NF-κB signaling pathway could differen-
tially regulate inﬂuenza A virus replication besides acting on viral initial
infections [10–12]. Similar to NF-κB, the C-jun N-terminal Kinases
(JNKs) signaling pathway has also been reported to be involved in
inﬂuenza A virus infections and replications [13,14]. Blockade of
JNK signaling pathway resulted in inhibition of IAV-induced JNK
and AP-1(activating protein-1) activation, and impaired the IFN-β
expression [14]. On the other hand, inhibition of JNK leads to prevention
of host cell apoptosis, an inevitable process for inﬂuenza virus infection
[15,16]. It was also demonstrated that SP600125, an inhibitor of JNK,
may interfere with IAV viral replication via NS1 [13].
C-jun is downstream of JNK and is a prototypical member of the
basic region-leucine zipper protein family, it forms homo- and/or
hetero-dimers, named AP-1, through the bZIP domain with other
proteins, such as Jun family, Fos family, activating transcription factor
(ATF) family, and musculoaponeurotic ﬁbrosarcoma (MAF) family [17,
18]. C-jun is the most extensively studied protein of the AP-1 complex
[19]. The steady elevation of c-jun expression is closely associated
with AP-1 activity [20]. C-jun is involved in numerous cell activities,
such as proliferation, apoptosis, survival and tumorigenesis [19]. It
became evident that c-jun/AP-1 can be activated by many extracellular
stimulators including viral infections, such as IAV [14,21]. In response to
IAV infection, c-jun is activated (phosphorylated) at a very early stage
[14] and can initiate and enhance the transcription of antiviral agents
such as IFN-β, and RANTES (Regulated on Activation, Normal T cell
Expressed and Secreted) [22], which can cause signiﬁcant inﬂamma-
tion. In addition, it was reported that the gene promoter of human
foamy virus (HFV) has a binding site for c-jun/AP-1 [23]. C-jun therefore
appears to have an important role in virus infections and replications.
DNAzymes are synthetic, single-stranded DNA catalysts that can be
engineered to bind to their complementary sequence contained in
target messenger RNA (mRNA) through Watson–Crick base pairing,
and cleave the mRNA at predetermined phosphodiester linkages [24].
Dz13, a catalytic DNA molecule cleaving c-jun mRNA [25], can inhibit
tumor growth and is a strong inhibitor of endothelial cell proliferation,
migration and tubule formation [26]. It was also reported that it could
abrogatemonocyte-endothelial cell adhesion in vitro and abolish leuko-
cyte rolling, adhesion and extravasation in a rat model of inﬂammation.
Dz13 also suppressed neutrophil inﬁltration in the lungs of mice
challengedwith endotoxin. All these ﬁndings implicate c-jun as a useful
target for anti-inﬂammatory therapies.
In the present study, we investigated whether inhibiting c-jun
activation (phosphorylation) could block the synthesis of inﬂammatory
cytokines and reduce virus replication, as a potential therapy strategyfor IAV infection. We demonstrated that suppression of c-jun in cells
and mice could efﬁciently reduce IAV replication and restore the
balance of pro- and anti-inﬂammation induced by IAV infection both
in vitro and in vivo.2. Methods
2.1. Ethics statement
Experimentation with animals was approved by the Animal Ethics
Committee of China Agricultural University (Approval number
201206078) and followed the Regulations of Experimental Animals of
Beijing Authority.2.2. DNAzymes
DNAzymes were synthesized with an inverted thymidine at the 3′
position (Tri-link Biotechnologies, San Diego, CA, USA) and puriﬁed
by high-pressure liquid chromatography. Sequences of Dz13 (a c-jun-
targeting DNAzyme bearing 9 + 9 nucleotide arms; cleavage junction
in c-jun mRNA is G1311U) and Dz13scr (sequence-scrambled counter-
part of Dz13) are 5′-CGGGAGGAAggctagctacaacgaGAGGCGTTG-Ti-3′,
and 5′-GCGACGTGAggctagctacaacgaGTGGAGGAG-Ti-3′. Nucleotides in
lower-case represent the 10–23 catalytic domain. Ti represents a 3′-
3′-linked inverted thymidine.2.3. Mice
Female BALB/c mice, 6–8 weeks old (Vital River Laboratories,
Beijing, China) were housed in independent ventilated cages and
received pathogen-free food and water.2.4. Virus
The H5N1 inﬂuenza virus (A/chicken/Henan/1/2004) used in
this study, which has the same receptor binding sites as A/Hong Kong/
156/97 (H5N1), was isolated from infected chicken ﬂocks. The virus
was propagated in Madin–Darby canine kidney (MDCK) cells at 37 °C
for 48 h, and then the viral supernatant was harvested, aliquoted, and
stored at −80 °C. The PFU and LD50 were determined in MDCK or
mice after serial dilution of the stock (8 × 107 PFU/ml and 3 × 106
LD50 respectively).
Fig. 2. c-jun activationwas inhibited byDz13 and c-jun downregulation suppressedH5N1 virus replication. (A) Activation of c-jun is attenuated byDz13 inH5N1 infectedA549 cells. A549
cellswere transfected twicewithDz13 andDz13scr and infectedwithH5N1. Cell lysateswere harvested at 6 h, 12h, and 24h p.i. and analyzedbyWestern blotting. (B)HAgeneexpression
was analyzed by real-time PCR. A549 cells were harvested at the indicated times after the second Dz13 and Dz13scr transfection and the followed H5N1 infection (N = 3). (C) c-jun
suppression by Dz13 attenuated H5N1 propagation in vitro. A549 cell supernatants were harvested 12 h, 24 h, and 36 h after H5N1 infection followed by two transfections with Dz13
and Dz13scr. Viral titers in cell supernatant were tested by plaque assay(N = 3),**, P b 0.01. (D) Time course of the effect of c-jun inhibitor on H5N1 virus production. A549 cells were
infected with H5N1 inﬂuenza A virus. Pharmacological treatment or a vehicle control (DMEM or DMSO) was applied at different times post-infection [−1 h, (1 h before infection); 1,
2, 3, 5, 7, 8, 9 and 11 h post- infection]. The virus titers in the supernatants at 12 h p.i. were determined by plaque assays, (N = 3) **, P b 0.01.
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Human lung adenocarcinoma epithelial A549 cell line was provided
by Cell Resource Center of Peking Union Medical College. A549 cells
were cultured in Dulbecco'smodiﬁed Eagle'smedium (Hyclone Labora-
tories, Beijing, China) containing 10% fetal bovine serum (Hyclone
Laboratories), 100 U/ml penicillin and 100 μg/ml streptomycin. The
cells were placed in serum-free medium to initiate growth arrest for
12 h, then we used FuGENE6 reagent (Roche, Indianapolis, IN, USA)
according to the manufacturer's instructions to transfect cells (at 60%–
75% conﬂuence) with Dz13 and its scrambled counterparts Dz13scr.
The transfected cells were incubated for 18 h in serum-free medium
and then performed second round of transfection in the same way.
At 6 h after transfection, cells were washed with phosphate-bufferedsaline (PBS) and infected with H5N1 inﬂuenza A virus (A/chicken/
Henan/1/2004) in serum-free DMEM (moi = 0.1). For some experi-
ments, virus was replaced for polyIC (50 ug/ml). The cells were shaken
gently every 10 min, then the supernatant was changed to DMEM
containing 1% fetal bovine serum.2.6. Administration of Dz13 to animals
The Dz13 were dissolved in PBS in a concentration of 200 μM, and
stored at−20 °C. Dz13 or its scrambled control at 2.5 mg/kg (in 50 μl
PBS containing 2.5 μl Fugene 6 and 1 mM MgCl2) was administrated
intranasally to H5N1 infected mice at day 0 (20 min after viral
challenge) and day 2 (48 h after viral challenge).
Fig. 3. c-jun suppression byDz13 alters inﬂammatory cytokine expression in vitro. The levels of (A) IFN-β, (B) IL-6, (C) TNF-α, and (D) IL-10mRNA inA549 cellswere detectedby real-time
PCR 24 h after two times transfections of Dz13 and Dz13scr and H5N1 infection (MOI = 0.1). (E) IFN-β, TNF-αmRNA in A549 cells were detected by real-time PCR 24 h after two times
transfections of Dz13 and Dz13scr and 50 ug/ml polyI:C (N = 3),*P b 0.05, **P b 0.01. C: control, D: Dz13, S: Dz13scr, V: H5N1, V/D: H5N1 plus Dz13, V/S: H5N1 plus Dz13scr.
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SP600125 (Beyotime, Haimen, Jiangsu, China) (molecular weight =
220) was dissolved in 100% DMSO (Dimethyl sulfoxide) at the concen-
tration of 20 mM for stock solutions. When administration, the A549
cells were incubated in DMEM medium containing 20 μM SP600125
for 1.5 h.
2.8. Viral challenge and sample collection
H5N1 virus stocks were diluted in PBS when used for infection. Mice
were anesthetized with intramuscular administration of Zoletil (Virbac,
Carros, France) and infected intranasally with 3LD50 in 50 μl. They were
sacriﬁced at various time-points and the lung tissues were stored in
liquid nitrogen. Lung tissue from each mouse was homogenized in1 ml PBS and centrifuged for 10 min at 1500 ×g and the supernatants
were stored at−80 °C for PFU assay.2.9. PFU assay
Madin–Darby canine kidney (MDCK) cell line was provided by Cell
Resource Center of Peking Union Medical College and was cultured in
the same conditions as A549 cells. The supernatants of mouse lung
tissues were diluted 10-fold and added to a monolayer of MDCK cells
in semi-solid agar that contained 0.5 μg/ml trypsin TPCK (Sigma-
Aldrich, St. Louis, MO, USA). Cultures were incubated at 37 °C, 5% CO2
for 60–72 h, then ﬁxed and stained with 1% crystal violet. Plaques
were counted, photographed and expressed as the mean log of
10 PFU/ml.
Fig. 4. C-jun suppression by SP600125 alters inﬂammatory cytokine expression in vitro. The levels of (A) IFN-β, (B) IL-6, (C) TNF-α, and (D) IL-10 mRNA in A549 cells were detected by
real-time PCR 24 h after SP600125 treatment and H5N1 infection (N= 3). *P b 0.05, **P b 0.01. C: control, DM: DMSO, V + DM: H5N1 plus DMSO, V + DM+ SP: H5N1 plus DMSO plus
SP600125.
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Cells or lung tissues were lysed in RIPA buffer (Beyotime, Haimen,
Jiangsu, China) with 10 mM PMSF (Beyotime) and 20 mM Cocktail
(Roche) on ice for 10–20 min. Lysis of tissues was assisted by grinding
with a grinding rod. Lysates were then centrifuged at 10,000 ×g for
10min to remove cell debris. Proteins in the supernatants were quanti-
tated by BCA protein assay (Applygen, Beijing, China) and resolved on
12% polyacrylamide gels and transferred to a polyvinylidene ﬂuoride
(PVDF) nylonmembrane (Millipore, Bedford,MA, USA). Themembrane
was then incubated with antibodies (Cell Signaling Technology,
Danvers, MA, USA) at 1:1000 ﬁnal dilution. The antibody binding
was detected with a Western Lightning chemiluminescence kit
(PerkinElmer Life Sciences, Boston, MA, USA).2.11. RNA extraction and qRT-PCR
RNAwas prepared from10mgof lung tissue or 1 × 106 cells homog-
enized in TRIzol reagent (Invitrogen, Carlsbad, CA, USA) in accordance
with the manufacturer's instructions. DNase I-treated RNA (0.2 μg)
was reverse transcribed into cDNA using EasyScript First-Strand cDNA
Synthesis SuperMix (TransGene, Beijing, China). Real-time PCR (qPCR)
was performed to amplify the genes using the Power SYBR® Green
PCR Master Mix kit (Applied Biosystems, Foster City, CA, USA). Primers
used are shown in sTable 1. The reactions were run on an ABI 7500
(Applied Biosystems) with the following steps: 95 °C for 10 min,
40 cycles of denaturation at 95 °C for 15 s, annealing at 56 °C for 30 s
and extension at 72 °C for 40 s. Data analysis was performed using ABI
7500 Software, version 2.0 (Applied Biosystems), which was provided
with the instrument.2.12. T cell analysis
Three mice were sacriﬁced 6 days after infection, while spleen
and peripheral blood lymphocyte (PBL) were harvested. The tissues
and bloodwerewashed and grinded, and subsequently the erythrocytes
were lysed by treatment with erythrocytes lysis buffer (M&C GENE,
Beijing, China). Single-cell suspensions were prepared by passing
through a nylon screen and washed in ﬂuorescence -activated cell
sorting diluent (PBS with 0.1% sodium azide and 2.0% fetal bovine
serum). Next, 200 ul of cell suspensions containing 106 cells was incu-
bated on ice for 1 h with combinations of ﬂuorescein isothiocyanate
(FITC)- and phycoerythrin (PE)-labeled antibodies (eBioscience, San
Diego, CA). Accordingly, lymphocyte populations were dual stained
with either FITC anti-mouse CD4 and PE anti-mouse CD8a or Cy5.5
anti-mouse CD3. The cells were then washed, resuspended in 1 ml of
2% paraformaldehyde, and analyzed on an Accuri C6 ﬂow cytometer
(Accuri Cytometers, Inc., Ann Arbor, MI). A total of 10,000 events,
gated for lymphocytes were performed in three independent
experiments.2.13. Histopathological analysis
Nose, trachea and lung tissues of mice were removed at the indicat-
ed days and ﬁxed with 4% neutral formalin at room temperature for
48 h. After embedding in parafﬁn, serial tissue sections were cut to
5 μm thickness, stainedwith hematoxylin and eosin (H&E). Histopatho-
logical changes were observed and scored under on Olympus micro-
scope (Olympus Optical Co. Ltd) by an independent pathologist.
Criteria for grading lung histopathological changes were as follows:
Grade 0 = no obvious pathological changes; Grades 1–3 = light
2484 J. Xie et al. / Biochimica et Biophysica Acta 1842 (2014) 2479–2488inﬂammatory cells inﬁltration, light hemorrhage, vasculitis or bronchi-
olitis; Grade 4–5 = inﬂammatory cells inﬁltration, hemorrhage, vascu-
litis or bronchiolitis, cell apoptosis and necrosis, microthrombus;
Grade 6–10 = severe inﬂammatory cells inﬁltration, severe hemor-
rhage, vasculitis or bronchiolitis, obvious edema, cell apoptosis and
necrosis, microthrombus, multinucleated giant cell.
2.14. Statistical analysis
Statistical analysis was performed by one-way ANOVA Tukey post
hoc test contained in the SPSS software or GraphPad Prism Software
(version 12.0; 2003, SPSS Taiwan Corp., Taiwan) (version5.0, GraphPad
Software, San Diego, CA) and P b 0.05 was considered statistically
signiﬁcant.Fig. 5. Suppression of c-jun improved the survival rate and health status of H5N1 virus infected
9; *, P b 0.05 by log rank analysis) and bodyweights were recorded daily. (B) Lung tissueswere c
blotting. Relative band intensity was determined digitally using QuantityOne 4.1.1 Software and
viral titers in lungs were determined by plaque assay and real-time PCR (N = 5). *P b 0.05, **P
topathology at day 6 p.i. Representative nose, trachea and lung sections from each groupwere s
open arrows indicate extravagated blood. Trachea: solid arrows indicate inﬁltration of inﬂamm
stitial edema and inﬂammatory cell inﬁltration around small blood vessels; open arrows indic
in bronchia. (E) The pathological scores of the tissues of infected mice. The pathological lesion3. Results
3.1. Acute response of c-jun expression upon IAV infection
To examinewhether c-junwas involved in H5N1 virus infection, we
studied the c-jun expression proﬁle upon H5N1 infection. Cells were
lysed at indicated times post-infection (p.i.) and Western blot analysis
was performed to detect activation of c-jun (phosphorylated). C-jun
activation kinetics started earlier than 2 h p.i. and reached a peak
value at 6–12 h p.i., there after returning to near basal levels at 24 h
(Fig. 1A).
To investigate the association between the kinetic proﬁles of c-jun
phosphorylation and IAV replication, we performed real-time PCR
using speciﬁc hemagglutinin (HA) gene primers to detect virusmice. (A) Surviving rates of mice uponH5N1 challenge and Dz13/Dz13scr treatment (N=
ollected on days 3 and 6 p.i., total and phospho-c-jun expressionwas analyzed byWestern
is expressed as a ratio of c-Jun toβ-actin. (C) c-jun affectedH5N1 propagation in vivo. The
b 0.01. C: control, V: H5N1, V/D: H5N1 plus Dz13, V/S: H5N1 plus Dz13scr (D) Lung his-
ubjected to H&E staining. Nose: solid arrows indicate inﬂammatory cell inﬁltration and the
atory cells, erythrocytes and/or dropout of epithelium. Lung: Solid arrows indicate inter-
ate abundant inﬂammatory cells, erythrocyte inﬁltration and drop of mucous epithelium
s were scored according to the method described in Materials and methods.
Fig. 5 (continued).
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phosphor-c-jun, the viral load in A549 cells exhibited a sustained
growth trend until 24 h. These results suggested that along with IAV
infection and replication, phosphor-c-jun may play a crucial part
in the initial process of H5N1 infection (6–12 h). Afterwards, activated
c-jun may be less involved in the sustaining of IAV replication.
3.2. Effect of c-jun down-regulation on H5N1 replication in A549 cells
To determine the effectiveness of Dz13, wemeasured the phosphor-
c-jun and total-c-jun levels in A549 cells infected H5N1 virus at 6 h 12 h
and 24 h post infection with or without Dz13 transfection. As shown in
Fig. 2A, at all the time points, Dz13 transfection of IAV-infected A549
cells markedly reduced the levels of both total and phosphorylated c-
jun expression. This validated Dz13 as an effective inhibitor of c-jun.
qPCR assayswere further performed on the viral RNA extracted from
the infected cells and shown that Dz13 could signiﬁcantly inhibit the
H5N1 virus replication at 12 h and 24 h p.i. (P b 0.05) (Fig. 2B). A plaque
assay for 12 h, 24 h, and 36 h p.i. was designed to further conﬁrm the
Dz13 suppressive effect on H5N1 virus replication. (Fig. 2C) (P b 0.05)
Results demonstrated that inhibition of c-jun could signiﬁcantly impact
on viral production.
Considering that the ﬁrst generation of inﬂuenza virus particles
release within 12 h after the initiation of infection [27], we further
determined which stage of the H5N1 virus life cycle was affected by c-
jun activation by using a small molecule inhibitor of JNK SP600125.
The inhibitor could effectively inhibit c-jun activation and reduce
H5N1 virus replication (Supplement Fig. 1B), but had no impact on
the level of total c-jun protein (Supplement Fig. 1A). When SP600125
was added to the cells at different time points including 1 h pre-
infection (−1), and 1, 2, 3, 5, 7, 8, 9, 11 h post infection and IAV infection
was carried out at the time 0, the viral replication could be obviously
suppressed by the JNK inhibitor from −1 h pre-infection to 7 h post
infection (P b 0.05) (Fig. 2D), indicating that the c-jun activation was
critically involved in the process of the IAV replication and production.
3.3. Effect of c-jun suppression on multiple pro-inﬂammatory cytokines
expression following H5N1 infection in A549 cells
H5N1 virus is a strong inducer of various pro-inﬂammatory
cytokines associated with acute respiratory syndrome [28]. As a crucial
factor of AP-1, c-jun is critical for the expression of IFN-β [5]. To investi-
gate the role of phosphor-c-jun suppression on inﬂammatory cytokine
expression in H5N1 infected cells, we analyzed IFN-β RNA expression
in A549 cells after two rounds of transfection of Dz13, followed by
H5N1 infection. Though the phosphor-c-jun level reached the peakvalue at 6 –12 h after infection, we chose 24 h p.i. as a measurement
to allow the infected cells having sufﬁcient time to express cytokines.
As shown in Fig. 3A, the expression of IFN-β mRNA was signiﬁcantly
decreased in Dz13 transfected cells in comparison with the scramble
Dz13 control (P b 0.05) [6]. In addition, we also found that suppression
of c-jun by Dz13 could strongly inhibit IL-6 and TNF-α expression
(Fig. 3B, C) (P b 0.05). In contrast, IL-10, an anti-inﬂammatory
cytokine, showed increased expression following c-jun inhibition
(Fig. 3D) (P b 0.05). These data suggested that inhibition of c-jun
expression could differentially regulate and balance the expression
of both pro- and anti-inﬂammatory cytokines.
To further explorewhether the regulation of the cytokine expression
by c-jun upon IAV infection was dependent on c-jun phosphorylation,
we employed the JNK inhibitor SP600125 to investigate its impact on
the cytokine expression in IAV-infected cells. Interestingly, inhibition
of c-jun activation by SP600125 could suppress both pro- and anti-
inﬂammatory cytokines including IFN-β, IL-6, TNF-α and IL-10 (Fig. 4)
(P b 0.05). This indicated that c-jun (SP600125) phosphorylation
could globally affect cytokine expression [22].
To conﬁrm that c-jun indeed regulates inﬂammation, instead of less
viral stimulus, we performed an additional experiment by using an
inﬂammatory stimulator polyIC to mimic IAV. The result demonstrated
the Dz13 could directly decrease the inﬂammatory cytokines (IFN-β,
TNF-α) expression upon the polyIC treatment (Fig. 3E), indicating that
c-jun is involved in RNA induced inﬂammation. These data ruled out
the possibility that the suppressed inﬂammatory response was due to
impaired viral replication.3.4. Improved survival of H5N1-infected animals by suppressing
c-jun expression
To investigate the roles of c-jun in H5N1 virus infection in vivo, we
challenged BALB/c mice with 3 LD50 of H5N1, and Dz13 was adminis-
tered twice at day 0 (20min after viral challenge) and day 2 via intrana-
sal route. Lung tissue samples of ﬁve mice per group were collected at
day 3 and day 6 for real-time PCR, plaque assay, and Western blotting
analyses. Tissue samples of the infected animals (nose, trachea and
lung) were collected on day 6 for histopathological analysis. Nine mice
per group were used to monitor the survival rate over 14 days. Results
showed that 55.5% of the Dz13 treatedmice survived at the termination
of the experiments (14 days p.i), while PBS treatedmice all died by day
9 and 11% of Dz13scr treated mice survived. The body weights of the
mice treated with Dz13 was higher than that of other groups (Fig. 5A).
When the mixed protein samples from the lung tissues of Dz13-
treated mice were analyzed by Western blotting, both total and
phosphorylated c-jun levels were shown to be down-regulated,
Fig. 6. c-jun suppression alters inﬂammatory cytokine expression in vivo. ThemRNA levels of (A) TNF-α, (B) IFN-β, (C) IL-6 and (D) IL-10 in the lung on days 3 and 6 p.i. were determined
by real-time PCR (N= 3). *P b 0.05. C: control, V: H5N1, V/D: H5N1 plus Dz13, V/S: H5N1 plus Dz13scr.
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c-jun down-regulation on viral replication in vivo, we examined the
viral load in lung tissues of H5N1 infected mice. Plaque assay and real-
time qPCR using H5N1 speciﬁc primers (HA genes) showed that the
pulmonary viral titer in H5N1 virus infected mice receiving Dz13 was
signiﬁcantly lower than that in mice treated with Dz13scr or PBS, both
on days 3 and 6 p.i. (P b 0.05) (Fig. 5C).
The pathological features of the respiratory tract in H5N1 infected
and c-jun suppressed mice are shown in Fig. 5D. Gross observation of
H5N1 infected mice treated with PBS (Fig. 5D, f) and Dz13scr (Fig. 5D,
h) demonstrated that the tracheal cavities were inﬁltrated with inﬂam-
matory cells, erythrocytes and epithelial cells, and there was an obvious
loss of tracheal epithelium inH5N1+ Dz13scr treatedmice. In contrast,
the trachea of Dz13 treatedmice (Fig. 5D, j) was characterized by only a
small amount of erythrocyte inﬁltration. The lung lesions in different
groups of mice, especially the H5N1 + PBS (Fig. 5D, j) and H5N1 +
Dz13scr (Fig. 5D, l) treated groups were characterized by interstitial
edema and inﬁltration of inﬂammatory cells around small blood vessels,
exfoliation of bronchiolar epithelium and epithelial cells, with erythro-
cytes and inﬂammatory cells in the alveolar lumen mixed with ﬂooded
edema ﬂuid. However, the symptoms were apparently mitigated in the
Dz13 treated group (Fig. 5D, k). Different from trachea and lung, the
nasal lesions were slight, with minor inﬂammatory cell inﬁltration
and extravasated blood only in the H5N1 + PBS (Fig. 5D, b) andFig. 7. c-jun suppression decreased the CD8+ T cells proliferation in vivo. T cell proﬁles in
spleen and PBLs by ﬂow cytometry (N= 3). *P b 0.05.H5N1 + Dz13scr (Fig. 5D, d) treated mice. Severity scores for lung
histopathological lesions are given in Fig. 5F [29]. These data indicat-
ed that down-regulation of c-jun in vivo could lessen the H5N1
virus-induced pathological damage, thus improved overall survival
of the infected animals.
3.5. IAV activated CD8+ T cell proliferation was affected by suppression
of c-jun
To determine whether c-jun could impact the CD8+ T cells prolifer-
ation, spleen tissue and PBL samples of three mice per group were
collected at day 3 and day 6 for ﬂow cytometry assay. Reduced levels
of CD8+ T cells were observed in H5N1 + Dz13 group compared with
PBS or Dz13scr treated mice both in spleen and PBL (Fig. 7).
3.6. c-jun regulation of cytokine expressions in vivo
To examine the role of c-jun on inﬂammation inH5N1 infectedmice,
analyses of IL-6, TNF-α, IFN-β, and IL-10 cytokine expression were
performed by real-time PCR on days 3 and 6 infection p.i. The mRNA
levels of IL-6, IFN-β and TNF-α in the Dz13 treated group were signiﬁ-
cantly reduced compared with the Dz13scr or PBS treated groups at
days 3 and 6 p.i. (P b 0.05). The expression of IFN-β and IL-6 mRNA at
day 6 p.i. was lower than that at day 3 p.i. (Fig. 6A–C). In contrast to
the proinﬂammatory cytokines, IL-10 showed a higher expression
level in Dz13 treated mice than that in other groups on both days 3
and 6 p.i. (Fig. 6D) (P b 0.05). Those, together with the observations in
cells, demonstrated the critical role of c-jun in initiation and regulation
of inﬂammatory responses to H5N1 virus infection both in vitro and
in vivo.
4. Discussion
JNK, a classic pathway involved in numerous cell activities, such
as proliferation, apoptosis and inﬂammation [30], is recognized as an
antiviral pathway in inﬂuenza infection, but under certain conditions
2487J. Xie et al. / Biochimica et Biophysica Acta 1842 (2014) 2479–2488it was shown to support inﬂuenza virus replication [13]. C-jun as a
downstream molecule of JNK and a crucial factor of activator protein
AP-1, may participate in the establishment of viral infection; however,
its role in H5N1 virus-induced inﬂammation remains to be elucidated.
Previous studies showed that c-jun/AP-1 was a key transcrip-
tion factor involved in cell proliferation, transformation, death and
differentiation [31]. An AP-1 binding site has been identiﬁed on retrovi-
rus promoters, which exerts an effect on the promoter activity of the
virus [23,32]. Although the IAV replication cycle does not contain a
DNA stage and transcription factors did not act directly on the IAV
promoter, it was demonstrated that NF-κB, a transcription factor with
similar functions to AP-1, could differentially activate inﬂuenza virus
RNA transcription from the cRNA promoter [11]. In the present study,
we used A549 cell line and a mouse model to examine whether c-jun
plays a critical role in H5N1 virus infection and replication. We showed
that c-jun was activated upon H5N1 infection in the ﬁrst replication
cycle of H5N1 virus (6 h to 12 h p.i.). Speciﬁc inhibition of c-jun expres-
sion by Dz13 led to signiﬁcant reduction of H5N1 virus replication.
Pharmacological inhibition of c-jun phosphorylation showed that
c-jun activation occurred at very early stage of the viral replication
[27,33], suggesting that c-jun participates in the establishment
of H5N1 inﬂuenza A virus replication. However, whether c-jun
activation is needed for viral entry is yet to be determined.
Inﬂammatory deregulation accompanying IAV infection has been
suggested to associate with the lethal dissemination of H5N1 inﬂuenza
virus [34]. The imbalance between pro-inﬂammatory and anti-
inﬂammatory cytokine expression could lead to host immunologic
injury [35]. We showed that once the viral infection was established, a
series of inﬂammatory responses were initiated in parallel accompany
with the elevated c-jun activation and expression. Down-regulation of
c-jun not only signiﬁcantly suppressed viral replication but alsomitigat-
ed the subsequent expression of inﬂammatory cytokines both in vitro
and in vivo. Intriguingly, we found that Dz13 down-regulation of c-
jun led to decreased expression of pro-inﬂammatory cytokines (IL-6,
IFN-β and TNF-α), and increased expression of anti-inﬂammatory cyto-
kine (IL-10). However, unlike Dz13, SP600125 inhibition of c-jun
phosphorylation caused the decreased expression of both pro- and
anti-inﬂammatory cytokines. Considering that Dz13 is an mRNA
sequence-speciﬁc inhibitor of c-jun and only impacts on the level of
expression while SP600125 acts by inhibiting c-jun phosphorylation,
we suggest that the level of total c-jun protein might drive balance of
pro- and anti- inﬂammatory cytokine expression in the context of IAV
infection,while c-jun activation (phosphorylation)may exert global im-
pact on cytokine expression. However, the data from the present study
could not rule out the possibility that SP600125may have weak impact
on other pathways in addition to JNK [36], whichmay be involved in the
regulation of IL-10 expression. Also, our data showed that suppression
of c-jun activation led to improved viral clearance and down-
regulated IFN-β, which seems to be contradictory. However, this in
turn supports our hypothesis that c-jun is an active regulator for both
viral replication and host inﬂammatory responses, in which IFN-β
could act as both antiviral and pro-inﬂammatory factor. Together, we
describe ﬁndings that indicate the novel dual functions of c-jun in
both establishing viral replication and initiating inﬂammatory reaction
in response to H5N1 virus infection.
Upon infection with inﬂuenza virus, CD4+ T cells, CD8+ T cells and
regulatory T cells are induced. CD8+ T cells differentiate into cytotoxic
cells to defend the host and secrete high levels of cytokines during the
cell-mediated immune response. The previously studies demonstrated
that JNK1 knock-down or use of the JNK inhibitor SP600125 markedly
reduced CD8+ T cell proliferation in mice, which is consistent with
our ﬁndings in the present study. However, in another study, the WT
and JNK1−/−mice showed the approximate T cell response to inﬂuen-
za virus [37–39]. The discrepancy between these observations may be
due to the different genetic background of the mice used in the studies,
which could lead to different host response to the viral infection.Use of the nucleic acid-based agents for antiviral therapeutics has
been explored for decades, which includes antisense oligonucleotides,
siRNA and DNAzymes [40,41] Due to its unique features in stability
and lower cost in manufacturing, DNAzyme has shown its potential in
down-regulation of the disease genes [42]. Recently, Dz13, a c-jun
targeted DNAzyme, has been successfully trialed in human and was
shown to be safe and efﬁcacious in the human skin cancer patients
[43]. Thus, it will be valued to explore the therapeutic potentials of
Dz13 in combating inﬂuenza infection. Indeed the use of anti-c-jun
DNAzyme may serve as a valuable and novel therapeutic strategy in
anti-inﬂuenza viral infection as shown in the present study. Our work
adds to the existing understanding of the complex regulatory network
that controls both the viral infection and host responses and promotes
anti-c-jun DNAzymes as a potential therapeutic target to control H5N1
infection and its sequelae.
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